---
title: "Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Guidelines questions"
description: "Guidelines questions on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: When did ACIP first publish Prevnar 20 recommendations for adults? Prevnar 20 after PCV13 and PPSV23: who is eligible under CDC recommendations? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Guidelines questions

Manufacturer: Wyeth Pharmaceutical Division of Wyeth Holdings LLC  
Prescribing information: [Prevnar 20](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428)

Questions that apply to every indication of Prevnar 20 are on [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications](https://www.evicenter.com/medical-information/prevnar-20).

## Guidelines

<a id="prevnar20-acip-history"></a>

### When did ACIP first publish Prevnar 20 recommendations for adults?

> “As of January 2022, ACIP first published their recommendations for use of Prevnar 20 in the Morbidity and Mortality Weekly Report.<sup>4</sup> It was later updated in September 2023 to include expanded use in certain previously vaccinated patients.<sup>5</sup>”

Source: [PREVNAR 20: Insurance Coverage, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/access-support#:~:text=As%20of%20January%202022%2C%20ACIP,use%20in%20certain%20previously%20vaccinated)

<a id="prevnar20-cdc-after-pcv13-ppsv23"></a>

### Prevnar 20 after PCV13 and PPSV23: who is eligible under CDC recommendations?

> “<sup>†</sup>If PCV13 was administered at any age and PPSV23 was administered before age 65 years with the last pneumococcal vaccine being at least 5 years prior, then the patient is eligible for Prevnar 20 as part of a routine vaccination. Based on shared clinical decision-making, a patient is eligible to receive Prevnar 20 if PCV13 (but not PCV15, PCV20, or PCV21) was administered at any age, PPSV23 was administered at or after the age of 65, and the last pneumococcal vaccine was at least 5 years prior.<sup>2</sup>”

Source: [PREVNAR 20: CDC Recommendations, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/cdc-recommendations#:~:text=PCV13%20was%20administered%20at%20any,was%20at%20least%205%20years)

> “<sup>‡</sup>Adults with chronic medical conditions were previously not recommended to receive PCV13, and there is no current CDC recommendation for those who have received both PCV13 and PPSV23.<sup>2,3</sup>”

Source: [PREVNAR 20: CDC Recommendations, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/cdc-recommendations#:~:text=with%20chronic%20medical%20conditions%20were,have%20received%20both%20PCV13%20and)

> “<sup>§</sup>Also applies to those with an immunocompromising condition (listed below) who have received PCV13 plus 2 doses of PPSV23.<sup>2</sup>”

Source: [PREVNAR 20: CDC Recommendations, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/cdc-recommendations#:~:text=applies%20to%20those%20with%20an,PCV13%20plus%202%20doses%20of)

Note: These footnotes are on the CDC Recommendations page of the Prevnar 20 HCP site, which cites the ACIP recommendations published in MMWR in 2025 and the CDC adult pneumococcal vaccine timing guide dated March 2025. They accompany a chart of eligible patient types that the captured page text does not reproduce. The CDC guidance cited is for pneumococcal conjugate vaccination, and Prevnar 20 (PCV20) is one of the vaccines it names.

## Related pages
- [Medical information: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults)
- [Indication](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/safety)
- [Specific populations](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/dosing-and-administration)
